These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

666 related items for PubMed ID: 29045077

  • 1. Subjective Complaints as the Main Reason for Biosimilar Discontinuation After Open-Label Transition From Reference Infliximab to Biosimilar Infliximab.
    Tweehuysen L, van den Bemt BJF, van Ingen IL, de Jong AJL, van der Laan WH, van den Hoogen FHJ, den Broeder AA.
    Arthritis Rheumatol; 2018 Jan; 70(1):60-68. PubMed ID: 29045077
    [Abstract] [Full Text] [Related]

  • 2. Assessment of effectiveness and safety of biosimilar infliximab (CT-P13) in a real-life setting for treatment of patients with active rheumatoid arthritis or ankylosing spondylitis.
    Codreanu C, Šírová K, Jarošová K, Batalov A.
    Curr Med Res Opin; 2018 Oct; 34(10):1763-1769. PubMed ID: 29439591
    [Abstract] [Full Text] [Related]

  • 3. Comparable long-term efficacy, as assessed by patient-reported outcomes, safety and pharmacokinetics, of CT-P13 and reference infliximab in patients with ankylosing spondylitis: 54-week results from the randomized, parallel-group PLANETAS study.
    Park W, Yoo DH, Jaworski J, Brzezicki J, Gnylorybov A, Kadinov V, Sariego IG, Abud-Mendoza C, Escalante WJ, Kang SW, Andersone D, Blanco F, Hong SS, Lee SH, Braun J.
    Arthritis Res Ther; 2016 Jan 20; 18():25. PubMed ID: 26795209
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Switching from originator to biosimilar infliximab - real world data of a prospective 18 months follow-up of a single-centre IBD population.
    Høivik ML, Buer LCT, Cvancarova M, Warren DJ, Bolstad N, Moum BA, Medhus AW.
    Scand J Gastroenterol; 2018 Jun 20; 53(6):692-699. PubMed ID: 29852793
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Efficacious transition from reference infliximab to biosimilar infliximab in clinical practice.
    Layegh Z, Ruwaard J, Hebing RCF, L' Ami MJ, van der Weele W, Nurmohamed MT, Krieckaert C, Wolbink G.
    Int J Rheum Dis; 2019 May 20; 22(5):869-873. PubMed ID: 30767391
    [Abstract] [Full Text] [Related]

  • 10. A 5-year Retrospective Analysis of Drug Survival, Safety, and Effectiveness of the Infliximab Biosimilar CT-P13 in Patients with Rheumatoid Arthritis and Ankylosing Spondylitis.
    Kim TH, Lee SS, Park W, Song YW, Suh CH, Kim S, Lee YN, Yoo DH.
    Clin Drug Investig; 2020 Jun 20; 40(6):541-553. PubMed ID: 32328979
    [Abstract] [Full Text] [Related]

  • 11. Efficacy and safety of CT-P13 (biosimilar infliximab) in patients with rheumatoid arthritis: comparison between switching from reference infliximab to CT-P13 and continuing CT-P13 in the PLANETRA extension study.
    Yoo DH, Prodanovic N, Jaworski J, Miranda P, Ramiterre E, Lanzon A, Baranauskaite A, Wiland P, Abud-Mendoza C, Oparanov B, Smiyan S, Kim H, Lee SJ, Kim S, Park W.
    Ann Rheum Dis; 2017 Feb 20; 76(2):355-363. PubMed ID: 27130908
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Switching from reference infliximab to CT-P13 in patients with inflammatory bowel disease: 12 months results.
    Argüelles-Arias F, Guerra Veloz MF, Perea Amarillo R, Vilches-Arenas A, Castro Laria L, Maldonado Pérez B, Chaaro Benallal D, Benítez Roldán A, Merino V, Ramirez G, Calleja-Hernández MA, Caunedo Álvarez A, Romero Gómez M.
    Eur J Gastroenterol Hepatol; 2017 Nov 20; 29(11):1290-1295. PubMed ID: 28902041
    [Abstract] [Full Text] [Related]

  • 17. A phase III randomized study to evaluate the efficacy and safety of CT-P13 compared with reference infliximab in patients with active rheumatoid arthritis: 54-week results from the PLANETRA study.
    Yoo DH, Racewicz A, Brzezicki J, Yatsyshyn R, Arteaga ET, Baranauskaite A, Abud-Mendoza C, Navarra S, Kadinov V, Sariego IG, Hong SS, Lee SY, Park W.
    Arthritis Res Ther; 2016 Apr 02; 18():82. PubMed ID: 27038608
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Retention rate and long-term safety of biosimilar CT-P13 in patients with ankylosing spondylitis: data from the Korean College of Rheumatology Biologics registry.
    Kim HA, Lee E, Lee SK, Park YB, Lee YN, Kang HJ, Shin K.
    Clin Exp Rheumatol; 2020 Apr 02; 38(2):267-274. PubMed ID: 31365335
    [Abstract] [Full Text] [Related]

  • 20. Efficacy and safety of biosimilar CT-P13 compared with originator infliximab in patients with active Crohn's disease: an international, randomised, double-blind, phase 3 non-inferiority study.
    Ye BD, Pesegova M, Alexeeva O, Osipenko M, Lahat A, Dorofeyev A, Fishman S, Levchenko O, Cheon JH, Scribano ML, Mateescu RB, Lee KM, Eun CS, Lee SJ, Lee SY, Kim H, Schreiber S, Fowler H, Cheung R, Kim YH.
    Lancet; 2019 Apr 27; 393(10182):1699-1707. PubMed ID: 30929895
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 34.